Scarica l'app Stockscreener
144.30
0.34%
0.49
Dopo l'orario di chiusura:
144.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$143.81
Aprire:
$143.77
Volume 24 ore:
9.16M
Relative Volume:
0.96
Capitalizzazione di mercato:
$356.01B
Reddito:
$65.51B
Utile/perdita netta:
$8.93B
Rapporto P/E:
40.61
EPS:
3.5532
Flusso di cassa netto:
$14.12B
1 W Prestazione:
-3.01%
1M Prestazione:
-4.84%
6M Prestazione:
+19.38%
1 anno Prestazione:
+61.21%
Intervallo 1D:
$142.73
$144.35
Intervallo di 1 settimana:
$142.73
$150.36
Portata 52W:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-02-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-13 | Ripresa | Citigroup | Neutral |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash - Stock Titan
Merck (MRK) director receives 111.8299 stock-linked units, payable 100% in cash after service ends. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
Merck reports tulisokibart results for Merck & Co. stock - AD HOC NEWS
Merck Says Investigational Skin Therapy Shows Potential - Benzinga
Merck nabs mid-stage trial win for skin disease drug (MRK:NYSE) - Seeking Alpha
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
A Look at Merck & Co Inc (MRK) After 0.4% Gain -- GF Value $120. - GuruFocus
Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank - MarketBeat
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - TradingView
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job? - Yahoo Finance
What Is Driving the Latest Milestones at Merck (NYSE:MRK)? - kalkinemedia.com
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer DrugMerck & Co (NYSE:MRK) - Benzinga
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - reuters.com
Daiichi, Merck withdraw BLA for B7-H3 ADC in small-cell lung cancer - BioWorld News
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication - TradingView
Merck closes SciBrunch KRAS licence worth up to US$2.13B - Mugglehead Investment Magazine
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
Merck & Co. stock trades at USD 148.74 after pipeline updates - AD HOC NEWS
B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing - insights.citeline.com
Merck (NYSE:MRK) In Focus As Oncology Advances And Pipeline Readouts Lift Its Shares Toward Rare Heights - kalkinemedia.com
Merck, Daiichi pull US application for second partnered cancer therapy - reuters.com
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years - Benzinga
Merck, Daiichi withdraw ifinatamab FDA application - Mugglehead Investment Magazine
Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS
Merck stock climbs 2.0 percent ahead of the open - AD HOC NEWS
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
Alpha Buying: Follow the Money From NVIDIA and Merck - Benzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine - Benzinga
What Is Driving the Latest Milestones at Merck & Co. (NYSE:MRK)? - Kalkine Media
Merck's drug for diabetes-related eye disease meets trial goal - reuters.com
Merck says remigromig met BRUNELLO vision endpoint, flags eye risks - Mugglehead Investment Magazine
Merck & Co. stock falls 1.86 percent as Q2 sales rise - AD HOC NEWS
Merck's experimental eye drug met its vision goal, but eye bleeding rates were higher than with the other drug - Stock Titan
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck and Co. stock falls 1.9 percent before the bell - AD HOC NEWS
QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Merck stock falls 2.63 percent at the close - AD HOC NEWS
Merck pipeline seen driving potential re-rating as clinical catalysts approach - Proactive financial news
Merck & Co. stock gains as Japan clears Keytruda injection - AD HOC NEWS
Merck and Co. stock gains 0.94 percent ahead of the open - AD HOC NEWS
Merck stock gains 1.97 percent at the close - AD HOC NEWS
State Street Corp Has $15.57 Billion Position in Merck & Co., Inc. $MRK - MarketBeat
MRK|Merck & Co Inc|Price:150.910|Chg%:+1.410 - TradingKey
Merck & Co. stock falls 36.58 percent year to date - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Bought by Andra AP fonden - MarketBeat
Merck: Time To Trim, Overvalued, And Overbought (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):